Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy

Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapyClinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy, Published online: 26 July 2018; doi:10.1038/s41571-018-0074-3The majority of patients receiving immunotherapy do not respond to treatment but might still have adverse events. Furthermore, some patients with an initial response will develop acquired resistance to treatment. In this Review, the authors describe the role of circulating tumour DNA in the management of patients receiving immunotherapy.

Source: Nature Clinical Practice Oncology - July 26, 2018 Category: Cancer & Oncology Authors: Luc Cabel Charlotte Proudhon Emanuela Romano Nicolas Girard Olivier Lantz Marc-Henri Stern Jean-Yves Pierga Fran çois-Clément Bidard Source Type: research